September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Intracameral Administration of a Sustained Release Bimatoprost Implant Efficiently Delivers Bimatoprost to Target Tissue Reducing Risk of Topical Prostaglandin Analog- Associated Adverse Events
Author Affiliations & Notes
  • Jennifer Seal
    Allergan plc, Irvine, California, United States
  • Shamira Perera
    Singapore National Eye Centre, Singapore, Singapore
  • Michael Coote
    Melbourne Eye Specialists, Melbourne, Victoria, Australia
  • Michael R Robinson
    Allergan plc, Irvine, California, United States
  • Patrick M Hughes
    Allergan plc, Irvine, California, United States
  • Alazar N Ghebremeskel
    Allergan plc, Irvine, California, United States
  • James A Burke
    Allergan plc, Irvine, California, United States
  • Mayssa Attar
    Allergan plc, Irvine, California, United States
  • Footnotes
    Commercial Relationships   Jennifer Seal, Allergan plc (E); Shamira Perera, Alcon (R), Allergan plc (C), Ellex (R), Ivantis (F); Michael Coote, Allergan plc (C), Allergan plc (R); Michael Robinson, Allergan plc (E); Patrick Hughes, Allergan plc (E); Alazar Ghebremeskel, Allergan plc (E); James Burke, Allergan plc (E); Mayssa Attar, Allergan plc (E)
  • Footnotes
    Support  Allergan plc
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3022. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jennifer Seal, Shamira Perera, Michael Coote, Michael R Robinson, Patrick M Hughes, Alazar N Ghebremeskel, James A Burke, Mayssa Attar; Intracameral Administration of a Sustained Release Bimatoprost Implant Efficiently Delivers Bimatoprost to Target Tissue Reducing Risk of Topical Prostaglandin Analog- Associated Adverse Events. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3022.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the ocular distribution of bimatoprost in dogs and safety in glaucoma patients after intracameral injection of a biodegradable sustained release bimatoprost implant (BimSR) vs repeated topical administration of bimatoprost 0.03% ophthalmic solution (generic formulation concentration).

Methods : Both eyes of 24 beagle dogs were administered bimatoprost 0.03% once daily for 7 days or an intracameral BimSR implant containing 15 μg bimatoprost. Ocular and periocular tissues were collected at relevant time points and bimatoprost concentrations were measured using liquid chromatography/tandem mass spectrometry and high-performance liquid chromatography. Prostaglandin analog (PGA) -associated ocular adverse events (AEs) or findings were evaluated from a 6 month interim analysis of a phase 1/2 clinical trial in 75 glaucoma patients receiving a BimSR injection in the study eye and daily topical bimatoprost in fellow eye.

Results : After BimSR administration in dogs, bimatoprost distributed primarily to tissues adjacent to the implant (ie iris-ciliary body [ICB], cornea, and aqueous humor); after topical bimatoprost administration the highest bimatoprost concentrations were found in ocular surface tissues (ie eyelid margins, bulbar conjunctiva, periorbital fat, cornea). Maximal bimatoprost concentration in ICB (target tissue) was higher after BimSR than after topical dosing. In glaucoma patients, PGA use-related AEs were more common in eyes treated with topical bimatoprost than in eyes treated with BimSR. Conjunctival hyperemia (onset later than 2 days) after BimSR injection was reported in 6.7% of study eyes compared with 17.6% of fellow eyes; eyelash growth was reported in no study eyes and 2.7% of fellow eyes. Orbital fat atrophy was observed in 2 patients in the fellow eye only receiving topical bimatoprost.

Conclusions : BimSR targeted the bimatoprost delivery to the ICB efficiently and more selectively than topical administration. Bimatoprost levels in bulbar conjunctiva, eyelid margin, and periorbital fat (potential AE associated tissues) were remarkably reduced or undetectable with BimSR. Consistent with this, compared with topical bimatoprost, BimSR was associated with reduced incidence of PGA use-related AEs in glaucoma patients in a phase 1/2 clinical trial.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×